Responses

Download PDFPDF
Original article
Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Switching anti-VEGFs in Tachyphylaxis
    • Kopal Mithal, Retina Fellow, LVPEI
    • Other Contributors:
      • Raja Narayanan

    Dear Editor,

    We read the article 'Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation' with interest. We congratulate the authors for trying to establish the efficacy of a promising treatment strategy for Tachyphylaxis to Anti-VEGF drugs in Exudative AMD. We agree with the authors that this could be a useful option in patients who develop tachyphylaxis. However, there are s...

    Show More
    Conflict of Interest:
    None declared.